Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 128,348,368
  • Shares Outstanding, K 957,038
  • Annual Sales, $ 22,320 M
  • Annual Income, $ 8,318 M
  • 60-Month Beta 0.34
  • Price/Sales 5.76
  • Price/Cash Flow 18.97
  • Price/Book 47.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 1.50
  • Number of Estimates 4
  • High Estimate 1.55
  • Low Estimate 1.47
  • Prior Year 1.33
  • Growth Rate Est. (year over year) +12.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
117.06 +14.57%
on 03/23/20
144.00 -6.87%
on 03/18/20
+4.92 (+3.81%)
since 02/27/20
3-Month
117.06 +14.57%
on 03/23/20
147.87 -9.31%
on 02/06/20
+2.59 (+1.97%)
since 12/27/19
52-Week
101.36 +32.31%
on 10/23/19
147.87 -9.31%
on 02/06/20
+5.34 (+4.15%)
since 03/27/19

Most Recent Stories

More News
Bristol Myers (BMY) Clinches FDA Nod for MS Drug Zeposia

The FDA approves Bristol Myers' (BMY) Zeposia for the treatment of adults with relapsing forms of multiple sclerosis.

PFE : 30.90 (-2.68%)
LLY : 134.11 (-0.18%)
BMY : 52.79 (+1.03%)
ABBV : 72.67 (-1.57%)
Pharma, Biotech Players Step Up Efforts Against Coronavirus

Several pharma & biotech companies announce their plan to fight coronavirus pandemic and state anticipated unfavorable impact of the outbreak on their business.

PFE : 30.90 (-2.68%)
MRK : 71.73 (-2.45%)
MYL : 14.88 (-4.25%)
LLY : 134.11 (-0.18%)
BMY : 52.79 (+1.03%)
AMGN : 198.27 (-0.11%)
Dow Soars More Than 20% Over 3-Day Win Streak

Dow Soars More Than 20% Over 3-Day Win Streak

SP : 21.92 (-9.12%)
GAIA : 8.03 (-0.99%)
AVID : 7.11 (-2.74%)
BABA : 188.59 (-3.45%)
MLNX : 119.79 (-0.59%)
WDC : 42.25 (-4.61%)
USFD : 18.02 (-4.96%)
MTZ : 29.50 (-6.88%)
ARNC : 16.68 (-5.87%)
LLY : 134.11 (-0.18%)
URI : 90.15 (-9.10%)
AIMT : 13.98 (-3.19%)
CLDR : 7.81 (-4.29%)
NWL : 13.61 (-3.54%)
TWOU : 21.98 (+1.01%)
Pfizer's Eczema Drug Eucrisa Gets FDA Approval for Infants

Pfizer (PFE) gets FDA approval for label expansion of Eucrisa to include children aged three months to two years with mild-to-moderate atopic dermatitis or eczema.

REGN : 449.52 (-0.61%)
SNY : 42.44 (-1.19%)
PFE : 30.90 (-2.68%)
LLY : 134.11 (-0.18%)
Agios' IND for PKR Activator AG-946 Gets FDA Clearance

The FDA passes Agios' (AGIO) investigational new drug application for its next-generation PKR activator, AG-946. The company plans to begin a phase I study on the same in mid-2020.

AZN : 42.47 (+0.26%)
LLY : 134.11 (-0.18%)
AGIO : 35.07 (-7.10%)
NEPH : 6.50 (+3.59%)
Lilly Halts Enrollment, Biotechs Focus to Find Coronavirus Cure

Supply-chain disruptions due to coronavirus outbreak may hurt biotech companies' first-quarter earnings. However, those making treatments/vaccines may make huge profits if their products get approval.

JNJ : 123.16 (-2.69%)
REGN : 449.52 (-0.61%)
SNY : 42.44 (-1.19%)
AZN : 42.47 (+0.26%)
GILD : 72.85 (-1.37%)
LLY : 134.11 (-0.18%)
GSK : 36.44 (-2.17%)
Updates from Lilly about insulin supply and affordability

To keep the diabetes community informed about important developments from the COVID-19 crisis, Eli Lilly and Company (NYSE: LLY) today is providing updates related to insulin supply and affordability:

LLY : 134.11 (-0.18%)
Lilly Gets CRL for Jardiance in Type I Diabetes Indication

Lilly's (LLY) label expansion application seeking approval of its type II diabetes medicine as a treatment for type I diabetes fails to get approval from the FDA.

JNJ : 123.16 (-2.69%)
NVO : 56.73 (-0.05%)
MRK : 71.73 (-2.45%)
LLY : 134.11 (-0.18%)
The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck

The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck

SNY : 42.44 (-1.19%)
RHHBY : 38.9650 (+0.48%)
PFE : 30.90 (-2.68%)
MRK : 71.73 (-2.45%)
LLY : 134.11 (-0.18%)
Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic

Eli Lilly and Company (NYSE: LLY) today provided an update on the company's clinical trial activities in light of the COVID-19 pandemic. The company will delay most new study starts and pause enrollment...

LLY : 134.11 (-0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade LLY with:

Business Summary

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their...

See More

Key Turning Points

2nd Resistance Point 141.39
1st Resistance Point 137.75
Last Price 134.11
1st Support Level 130.33
2nd Support Level 126.56

See More

52-Week High 147.87
Last Price 134.11
Fibonacci 61.8% 130.10
Fibonacci 50% 124.61
Fibonacci 38.2% 119.13
52-Week Low 101.36

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar